Survival, mortality and causes of death in inflammatory myopathies

References

• Medsger TA, Robinson H, Masi AT. Factors affecting survivorship in polymyositis: A life table study of 124 patients. Arthritis Rheum 1971; 14: 249–258
   PubMedGoogle Scholar
• Benbassat J, Gefel D, Larholt K, Sukenik S, Morgenstrern V, Zlotnick A. Prognostic factors in polymyositis/dermatomyositis. A computer assisted analysis of ninety-two cases. Arthritis Rheum 1985; 28: 249–255
   PubMed Web of Science ®Google Scholar
• Maugars YM, Berthelot JMM, Abbas AA, Mussini JMB, Nguyen JMD, Prost AM. Long term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996; 14: 263–274
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, Courtois H. Polymyositis and dermatomyositis: Short term and long term outcome, and predictive factors of prognosis. J Rheumatol 2001; 28: 2230–2237
   PubMed Web of Science ®Google Scholar
• Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: Morbidity and mortality. Rheuamtology 2002; 41: 22–26
   PubMed Web of Science ®Google Scholar
• Dankó K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long term survival of patients with idiopathic inflammatory myopathies according to clinical features. A longitudinal study of 162 cases. Medicine 2004; 83: 35–42
   PubMed Web of Science ®Google Scholar
• Chinoy H, Ollier WER, Cooper RG. Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies?. Curr Opin Rheumatol 2004; 16: 707–713
   PubMedGoogle Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis. Parts 1 and 2. New Engl J Med 1975; 292: 344–347, 403-7
   PubMed Web of Science ®Google Scholar
• Askanas V, Engel WK. New advances in inclusion body myositis. Curr Opin Rheumatol 1993; 5: 732–741
   PubMedGoogle Scholar
• Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977; 56: 255–286
   PubMed Web of Science ®Google Scholar
• Huber AM, Lang B, LeBlanc CMA, et al. Medium and long term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 541–549
   PubMed Web of Science ®Google Scholar
• Ponyi A, Constantin T, Balogh Z, et al. Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. Clin Exp Rheumatol 2005; 23: 50–56
   PubMedGoogle Scholar
• Rider LG, Miller FW, Targoff IN, et al. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 1994; 37: 1534–1538
   PubMed Web of Science ®Google Scholar
• Garton MJ, Isenberg DA. Clinical features of lupus myositis versus idiopathic myositis: A review of 30 cases. Br J Rheumatol 1997; 36: 1067–1074
   PubMedGoogle Scholar
• Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Sem Arthritis Rheum 1986; 15: 168–178
   PubMed Web of Science ®Google Scholar
• Grau JM, Miró O, Pedrol E, et al. Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. J Rheumatol 1996; 23: 1921–1926
   PubMed Web of Science ®Google Scholar
• Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Care Res 2002; 47: 614–622
   Google Scholar
• Schnabel A, Reuter M, Biederer J. Interstitial lung disease in polymyositis and dermatomyositis: Clinical course and response to treatment. Sem Arthritis Rheum 2003; 32: 273–284
   PubMed Web of Science ®Google Scholar
• Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004; 63: 297–301
   PubMed Web of Science ®Google Scholar
• Wakata N, Kurihara T, Saito E, Kinoshita M. Polymyositis and dermatomyositis associated with malignancy: A 30 year retrospective study. J Dermatol 2002; 41: 729–734
   Google Scholar
• Hill CL, Zhnag Y, Sigurgeirsson B, Pukkala E, Mellenkjaer L, Airio A, Evans SR. Frequency of specific cancer types in dermatomyositis and polymyositis: A population based study. Lancet 2001; 357: 96–100
   PubMed Web of Science ®Google Scholar
• Buchbinder R, Forbes A, Hall S, Dennet X, Giles G. Incidence of malignant disease in biopsy proven inflammatory myopathy. A population based cohort study. Ann Intern Med 2001; 134: 1087–1095
   PubMed Web of Science ®Google Scholar
• Callen JP. Relationship between dermatomyositis and polymyositis and cancer. Lancet 2001; 357: 85–86
   PubMedGoogle Scholar
• Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002; 81: 154–167
   PubMed Web of Science ®Google Scholar
• Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis. Demographic, clinical and serological features and survival in 1012 Italian patients. Medicine 2002; 81: 139–153
   PubMed Web of Science ®Google Scholar
• Follansbee WP, Zerbe TR, Medsger TA. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): A high risk association. Am Heart J 1993; 125: 194–203
   PubMed Web of Science ®Google Scholar